New EU Rule Eases Biosimilar Development
The European Medicines Agency has published draft guidelines on biosimilars with monoclonal antibodies, loosening some restrictions on development of the drugs, which are used to treat cancer and autoimmune diseases....To view the full article, register now.
Already a subscriber? Click here to view full article